Nick Devoogdt is a molecular biologist and works as a full professor heading a team at the Free University of Brussels, applying nanobodies as vehicles for imaging and therapy in oncology, inflammation, and cardiovascular diseases. He obtained an MSc in Molecular Biology in 1997 and a PhD in Applied Biological Sciences in 2004 at the Free University of Brussels, working on cancer genetics and investigating the interaction between cancer cells and tumor-infiltrating macrophages. From 2004 to 2005, he was a visiting scientist at the National Cancer Institute in Bethesda, USA, studying ovarian cancer genetics and biomarkers. He returned to the Free University of Brussels to fulfill several postdoctoral positions, at first continuing research on cancer genetics and the interplay between cancer cells and their microenvironment. During these studies, he got acquainted with antibody engineering and became skilled in nanobody technology. His current focus is the use of nanobodies to imaging and treat cancer and inflammatory diseases, with a strong focus on preclinical development and clinical translation. In 2014, he co-founded the Brussels spinoff company PRECIRIX and in 2020 ABSCINT, where he is still active as a scientific advisor.